Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action

NCT01770145 is registered in ClinicalTrials.gov with MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals as lead sponsor.

NCT NCT01770145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01770145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2012
Completion date
April 30, 2014
Enrollment
127 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

akinesia, delayed levodopa onset, hypomobility, motor symptoms, parkinson's disease